# Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

> **NCT02038881** · PHASE2 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 87 (actual)

## Conditions studied

- Smallpox

## Interventions

- **BIOLOGICAL:** IMVAMUNE®

## Key facts

- **NCT ID:** NCT02038881
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-28
- **Primary completion:** 2017-05-10
- **Final completion:** 2017-05-10
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2020-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02038881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02038881, "Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02038881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*